Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Mundipharma Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (127)
ARTG (90)
Australian Public Assessment Report (AusPAR) (9)
Prescription medicine registration (2)
Cancellation or suspension (1)

Date

2026 (9)
2025 (4)
2024 (16)
2023 (1)
2022 (62)
2021 (3)
2020 (28)
2019 (5)
2018 (7)
2017 (19)
2016 (5)
2015 (8)
2014 (7)
2013 (13)
2012 (1)
2011 (2)
2010 (7)
2005 (6)
2003 (3)
2001 (3)
2000 (7)
1999 (4)
1996 (1)
1995 (3)
1993 (3)
1991 (2)

Search

Sponsor content

229 result(s) found, displaying 1 to 10

DILAUDID hydromorphone hydrochloride 2mg/1mL injection ampoule Cancelled under Section 30(1)(c) of the Act

2 June 2026

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
DILAUDID-HP hydromorphone hydrochloride 10mg/1mL injection ampoule Cancelled under Section 30(1)(c) of the Act

2 June 2026

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
DILAUDID-HP hydromorphone hydrochloride 50mg/1mL injection ampoule Cancelled under Section 30(1)(c) of the Act

2 June 2026

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
SEVREDOL morphine sulfate pentahydrate 20mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 May 2026

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
SEVREDOL morphine sulfate pentahydrate 10mg tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 May 2026

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
BI ELIGARD CP (Eligard 3 month 22.5mg and MPL-Bicalutamide 50mg, 28 pack) Cancelled under Section 30(1)(c) of the Act

25 May 2026

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
BI ELIGARD CP (Eligard 3 month 22.5mg and MPL-Bicalutamide 50mg, 84 pack) Cancelled under Section 30(1)(c) of the Act

25 May 2026

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
BI ELIGARD CP (Eligard 1 month 7.5mg and MPL-Bicalutamide 50mg, 28 pack) Cancelled under Section 30(1)(c) of the Act

25 May 2026

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
MPL-BICALUTAMIDE bicalutamide 50mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

25 May 2026

Cancellation by sponsor

Requested by Mundipharma Pty Ltd
ARX-Oxycodone/Naloxone oxycodone hydrochloride / naloxone hydrochloride 20/10 mg modified release tablets blister pack (446592)

8 October 2024

ARTG

Australian Register of Therapeutic Goods (ARTG) information for ARX-Oxycodone/Naloxone oxycodone hydrochloride / naloxone hydrochloride 20/10 mg modified release tablets blister pack.

Pages

Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.